We are live on
!
Find out more
RA
Rosalind Advisors Portfolio holdings
AUM
$249M
1-Year Est. Return
80.12%
This Fund
S&P 500
This Quarter
Est. Return
+19.75%
1 Year Est. Return
+80.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$156M
AUM Growth
+$26.2M
(+20%)
Cap. Flow
+$107M
Cap. Flow
% of AUM
68.62%
Top 10 Holdings %
Top 10 Hldgs %
70.44%
Holding
44
New
5
Increased
13
Reduced
10
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CorMedix
CRMD
|
+$7.98M |
| 2 |
HELP
Cybin Inc
HELP
|
+$5.61M |
| 3 |
Cellectar Biosciences
CLRB
|
+$2.12M |
| 4 |
MediWound
MDWD
|
+$2.09M |
| 5 |
Myomo
MYO
|
+$1.48M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Viridian Therapeutics
VRDN
|
+$3.9M |
| 2 |
ABVX
Abivax
ABVX
|
+$2.86M |
| 3 |
CLSD
Clearside Biomedical
CLSD
|
+$2.81M |
| 4 |
Trevi Therapeutics
TRVI
|
+$1.91M |
| 5 |
Rezolute
RZLT
|
+$1.07M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Biofrontera
BFRI
$15.7M
| $659K | 0.42% |
495,490
-8,771
| -2% | -$10K |
|
27
Talphera
TLPH
$70.1M
| $650K | 0.42% |
758,966
| – | – |
|
28
Journey Medical
DERM
$178M
| $598K | 0.38% |
105,917
-8,215
| -7% | -$42.3K |
|
29
PUT
Invesco QQQ Trust
QQQ
$450B
| $221K | 0.14% |
+150,000
| New | +$71M |
|
30
NewAmsterdam Pharma
NAMS
$3.33B
| $168K | 0.11% |
10,123
| – | – |
|
31
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
| $164K | 0.11% |
200,000
+177,597
| +793% | +$17.4M |
|
|
CLSD
32
DELISTED
Clearside Biomedical
CLSD
| $162K | 0.1% |
8,481
-164,359
| -95% | -$2.81M |
|
33
Vor Biopharma
VOR
$1.18B
| $53.7K | 0.03% |
+3,834
| New | +$69.9K |
|
34
PUT
Annovis Bio
ANVS
$75.3M
| – | – |
-24,154
| Closed | -$839K |
|
35
BioXcel Therapeutics
BTAI
$24.5M
| – | – |
-2,480
| Closed | -$50.8K |
|
36
Geron
GERN
$860M
| – | – |
-200,000
| Closed | -$848K |
|
|
LYRA
37
DELISTED
LYRA THERAPEUTICS INC
LYRA
| – | – |
-20,695
| Closed | -$286K |
|
|
38
Rezolute
RZLT
$470M
| – | – |
-250,000
| Closed | -$1.07M |
|
39
Tonix Pharmaceuticals
TNXP
$161M
| – | – |
-282
| Closed | -$19.6K |
|
40
Unicycive Therapeutics
UNCY
$145M
| – | – |
-157,120
| Closed | -$787K |
|
|
41
Viridian Therapeutics
VRDN
$2.2B
| – | – |
-300,000
| Closed | -$3.9M |
|
42
Beyond Air
XAIR
$3.91M
| – | – |
-2,259
| Closed | -$486K |
|
|
SPRB
43
Spruce Biosciences
SPRB
$119M
| – | – |
-20,112
| Closed | -$781K |
|
|
GTHX
44
PUT
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| – | – |
-19,018
| Closed | -$305K |
|
Similar funds
TAM
SCM
FDDB
MC
SCM
GWS
SCM
ER
Rosalind Advisors's Q3 2024 Portfolio in Review
As of Q3 2024, Rosalind Advisors held 44 positions worth $156M, up 20% from $130M the previous quarter. Its ten largest holdings account for 70% of the portfolio.
Rosalind Advisors deployed $107M of net new capital in Q3 2024, opening 5 new positions and adding to 13 existing holdings. Its largest new stake was CorMedix: 1,475,000 shares worth $11.9M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier.
On the sell side, the largest reduction was Abivax, an estimated $2.86M trimmed.
- Rosalind Advisors's largest Q3 2024 buy was CorMedix: 1,475,000 shares worth $11.9M.
- Rosalind Advisors added most to Cybin Inc in Q3 2024, an estimated $5.61M increase.
- Rosalind Advisors's biggest Q3 2024 reduction was Abivax, cutting an estimated $2.86M.
- Rosalind Advisors fully exited Viridian Therapeutics in Q3 2024, selling an estimated $3.9M.
- Rosalind Advisors's ten largest holdings make up 70% of its $156M portfolio in Q3 2024.
- Rosalind Advisors opened 5 new positions and closed 11 in Q3 2024.
- Rosalind Advisors's portfolio value rose 20% quarter-over-quarter to $156M.
Based on Rosalind Advisors's 13F filing for Q3 2024, filed 30 Oct 2024.